Blog
RSS FeedPosted by Michael Wonder on 15 Jun 2020
Jazz Pharmaceuticals announces U.S. FDA accelerated approval of Zepzelca (lurbinectedin) for the treatment of metastatic small cell lung cancer
15 June 2020 - Zepzelca is approved under accelerated approval based on overall response rate and duration of response demonstrated in ...
Posted by Michael Wonder on 13 Jun 2020
FDA approves Merck’s Gardasil 9 for the prevention of certain HPV related head and neck cancers
12 June 2020 - Gardasil (human papillomavirus 9 valent vaccine, recombinant) now approved for the prevention of HPV related cervical, ...
Posted by Michael Wonder on 12 Jun 2020
FDA approves drug to treat infants and children with HIV
12 June 2020 - Today, the U.S. Food and Drug Administration approved Tivicay (dolutegravir) tablets and Tivicay PD (dolutegravir) tablets for ...
Posted by Michael Wonder on 12 Jun 2020
Mylan and Biocon announce U.S. FDA approval of Semglee (insulin glargine injection)
11 June 2020 - FDA approval marks a significant milestone to help increase access and affordability of insulin for the millions ...
Posted by Michael Wonder on 11 Jun 2020
FDA approves Pfizer's oncology supportive care biosimilar Nyvepria (pegfilgrastim-apgf)
11 June 2020 - Pfizer today announced the United States FDA has approved Nyvepria (pegfilgrastim-apgf), a biosimilar to Neulasta (pegfilgrastim). ...
Posted by Michael Wonder on 11 Jun 2020
FDA approves new therapy for rare disease affecting optic nerve, spinal cord
11 June 2020 - Second FDA approved therapy for neuromyelitis optica spectrum disorder offers patients additional treatment option. ...
Posted by Michael Wonder on 11 Jun 2020
U.S. Food and Drug Administration approves Opdivo (nivolumab) for the treatment of patients with advanced oesophageal squamous cell carcinoma after prior fluoropyrimidine- and platinum-based chemotherapy
10 June 2020 - Opdivo demonstrated superior overall survival benefit compared to docetaxel or paclitaxel. ...
Posted by Michael Wonder on 11 Jun 2020
US FDA approves updated Novartis Beovu label to include additional safety information
11 June 2020 - Novartis worked with US FDA to update Beovu (brolucizumab) prescribing information to guide healthcare professionals in their ...
Posted by Michael Wonder on 04 Jun 2020
FDA approves antibiotic to treat hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia
4 June 2020 - Today, the U.S. Food and Drug Administration approved Recarbrio (a combination of imipenem-cilastatin and relebactam) to treat ...
Posted by Michael Wonder on 03 Jun 2020
Helsinn Group announces FDA approval of a new liquid formulation of Akynzeo (fosnetupitant/palonosetron) injection in the United States
2 June 2020 - Helsinn today announces that the U.S. FDA has approved the ready-to-dilute liquid formulation of Akynzeo (fosnetupitant/palonosetron) ...
Posted by Michael Wonder on 01 Jun 2020
Brilinta approved in the US to reduce the risk of a first heart attack or stroke in high-risk patients with coronary artery disease
1 June 2020 - New Brilinta indication expands treatment to high-risk coronary patients without a history of stroke or heart ...
Posted by Michael Wonder on 01 Jun 2020
Lilly's Taltz (ixekizumab) is the first IL-17A antagonist to receive U.S. FDA approval for the treatment of non-radiographic axial spondyloarthritis
1 June 2020 - Taltz is now approved to treat patients across the full axSpA spectrum, including ankylosing spondylitis, also known ...
Posted by Michael Wonder on 01 Jun 2020
Zionexa USA and PETNET Solutions announce FDA approval of Cerianna (Fluoroestradiol F 18)
27 May 2020 - Zionexa USA and PETNET Solutions have announced that the FDA has approved Cerianna (fluoroestradiol F 18) injection ...
Posted by Michael Wonder on 01 Jun 2020
U.S. FDA approves new paediatric formulation of Sirturo (bedaquiline) as part of combination therapy to treat children with pulmonary multidrug-resistant tuberculosis
27 May 2020 - The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the U.S. FDA has granted ...
Posted by Michael Wonder on 01 Jun 2020
Menlo Therapeutics receives FDA approval of Zilxi (minocycline) 1.5 % topical foam, the first topical minocycline treatment for rosacea
29 May 2020 - Zilxi now approved for inflammatory lesions of rosacea in adults. ...